Imagine trying to grow a perfect crystal in a jar, but gravity keeps pulling the ingredients down and making them clump. By moving the process to space, everything floats, allowing proteins to form much purer and more precise structures. This project builds a tiny, remote-controlled factory that does this in orbit to create better medicines.
Traditional drug development is limited by Earth's gravity, which reduces the purity and stability of complex biological products. This leads to expensive development timelines and frequent clinical trial failures.
A 24 kg automated, modular drug manufacturing facility (MOTI) featuring lab-on-a-chip technology and docking interfaces for the SpaceRider vehicle.
If you are a mAb developer dealing with low purity and stability in complex biological products — this project developed a 24 kg automated space facility that produces superior quality compounds in microgravity.
If you are a cancer drug research firm dealing with high clinical trial failure rates — this project developed a lab-on-a-chip micro-factory that accelerates preclinical testing of complex proteins.
If you are a satellite operator dealing with underutilized payload capacity — this project developed a modular unit compatible with any launcher to enable industrial-grade biomanufacturing in orbit.
Based on available project data, specific pricing is not listed, but the objective is to provide an affordable drug development alternative to terrestrial methods.
The project aims to shift from R&D to manufacturing using a scalable and modular building block called MOTI to enable industrial-grade production.
Based on available project data, there is no specific mention of licensing terms or patent numbers.
The project period runs from 2024-08-01 to 2026-07-31, focusing on validating the unit and executing a commercial demonstration mission.
The unit is designed to be 24 kg, meet ESA safety standards, and is compatible with the SpaceRider vehicle and other launchers.
The project is led by a single SME, SPACEPHARMA R&D ISRAEL LTD, resulting in a 100% industry ratio. This lean structure suggests a fast-moving, commercially driven approach rather than an academic one, though it lacks the diversified expertise of a multi-partner consortium.
Contact SPACEPHARMA R&D ISRAEL LTD regarding the MOTI building block
Contact us to match with space-based biomanufacturing partners.
